Built for evidence synthesis professionals

Systematic reviews, done right and on time.

AI-assisted screening, extraction, and risk of bias — from first import to PRISMA-ready export. Every decision human-confirmed. Every step auditable.

app.rigora.com/reviews/glp1-cv/screening
AI: INCLUDE23 of 847 screened · 40 included · 9 uncertain

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

INCLUDE

Lincoff AM et al. · N Engl J Med · 2023

A multicenter, double-blind, randomized, placebo-controlled trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg on major adverse cardiovascular events in adults with preexisting cardiovascular disease and a body-mass index of 27 or higher but without diabetes…

AI rationale:RCT in adults with established CVD and BMI ≥27 on semaglutide (GLP-1 RA) with MACE primary outcome and 40-month follow-up — meets all inclusion criteria.

EexcludeUuncertainIincludenext
Meets reporting requirements forPRISMA 2020Cochrane LibraryNEJMNICECADTHICER

60–80%

Reduction in screening time

AI pre-screens every abstract. You confirm.

100%

Human-confirmed decisions

Every AI output requires your sign-off before export.

PRISMA 2020

Flow diagram auto-generated

SVG download ready for manuscript submission.

Everything the Workflow Requires

From first import to final PRISMA diagram — without switching tools, rebuilding spreadsheets, or losing the audit trail.

AI-Assisted Screening

Claude evaluates every abstract against your inclusion and exclusion criteria. Returns INCLUDE / EXCLUDE / UNCERTAIN with a one-sentence rationale. You confirm or override — every decision is logged.

Cuts screening time 50–80%

Structured Data Extraction

Define your extraction schema once. AI fills every field and cites the exact sentence from the paper. Reviewers confirm field by field. Exports to CSV the moment you're done.

Source citation required for every field

Risk of Bias Assessment

Pre-fills RoB 2.0 (RCTs) and ROBINS-I (observational studies) domain by domain with supporting quotes from the full text. Traffic light summary table auto-generates across all included studies.

RoB 2.0 · ROBINS-I · Cochrane-compatible

The Full Systematic Review Workflow

One platform from search strategy to PRISMA diagram. No spreadsheets, no tool-switching, no lost audit trail.

01

Search Strategy

Log databases, boolean strings, and records found. Feeds PRISMA counts automatically.

02

Reference Import

Drag-and-drop RIS or CSV. Automatic deduplication by DOI and normalized title.

03

AI Screening

Abstract-level pre-screening with INCLUDE / EXCLUDE / UNCERTAIN. Keyboard or swipe on mobile.

04

Extraction & RoB

Schema-defined data extraction with source citations. RoB 2.0 and ROBINS-I pre-fill.

05

Export & Report

PRISMA 2020 SVG, extracted data CSV, screening log, audit trail. Submission-ready.

Built for Rigorous Review Teams

Designed for buyers who know what Cohen's kappa is and why it matters.

Pharmaceutical evidence teams

Safety reviews, label updates, HTA submissions. Defensible methodology with a full audit trail your regulatory team can stand behind. Your data stays yours — always.

HTA agencies

NICE, CADTH, ICER, and equivalent bodies. Tools that match the methodological standards you already apply to the evidence you receive.

Systematic review consultancies

Firms producing reviews for pharma, HTA agencies, and guideline bodies. Run more reviews at higher margin without adding headcount.

Academic research groups

Well-funded groups doing 5–20 reviews a year. Spend your time on judgment calls, not spreadsheet maintenance.

How Rigora Compares

Covidence and Rayyan are widely used. Here is where each one stops — and where Rigora starts.

Feature
Rigora
CovidenceRayyan
Starting priceFree$339 / reviewFree (3 reviews)
Full workflow — screening through export
AI-native extraction with source citations
Your data belongs to youIP risk
PRISMA 2020 flow diagram
RoB 2.0 / ROBINS-I
Full audit trail
Living review support
Network meta-analysis

Rayyan's Terms of Service (§7) grant a perpetual, royalty-free license to use all content you upload — including screening decisions and extracted data. For proprietary pharma evidence, this is a material data governance risk. Covidence pricing as of 2025.

Journal Readiness Built In

Every requirement tracked in real time. No checklist archaeology at submission.

PRISMA 2020 flow diagram — auto-generated SVG
PROSPERO pre-registration — captured at setup
Search strategy — full boolean strings per database logged
Two-reviewer screening — decisions tracked per user
Inter-rater reliability — Cohen's κ calculated live
Risk of bias — RoB 2.0 domain-by-domain with traffic light summary
Data extraction with source citations — AI extracts, human confirms
Audit trail — every decision timestamped and attributed

Simple, Transparent Pricing

A full systematic review costs $50,000–$250,000 in researcher hours. Rigora compresses that by 60–80%. The math is straightforward.

Free

$0

1 review · 200 references · All AI features included

Get started

Pro

$79/month

Unlimited reviews · 2,000 refs/review · Full workflow · Audit trail

Start Pro

Team

$249/month

5 seats · Two-reviewer workflow · Conflict resolution · Cohen's κ

Start Team

See full pricing — Institutional, LMIC ($15/month), and annual plans →

Start with one review. No credit card required.

The free tier supports a full review end-to-end — up to 200 references. Every AI feature included. See how it works before you commit.

Questions? hello@rigora.com